Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0HGQF5
Wed, 09.02.2022
MagForce AG
In the past fiscal year 2021, MagForce AG made progress in both business
segments. Of particular note here is the approval granted by the FDA for
the start of Stage 2b for the treatment of prostate cancer patients. This
means that the pivotal study could be concluded as early as summer 2022. In
parallel, the treatment capacities for the indication [ … ]
Mon, 20.12.2021
MagForce AG
MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
Stage 2b of the single arm study will enroll up to 100 men who have progressed to intermediate risk prostate cancer stage and are under active surveillance
First p [ … ]
Mon, 15.11.2021
MagForce AG
1st HY 2021: FDA approval for final pivotal study received, forecasts and
price target confirmed, rating: BUY
In the context of the research study (Anno) of 20.07.2021, we had already
postulated our expectations that MagForce AG would probably report low
treatment figures overall in Europe (indication area: glioblastoma) in the
first half of 202 [ … ]
Fri, 05.11.2021
MagForce AG
MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Following FDA green-light, Stage 2b of the pivotal trial will begin immediately
Patient screening and enrollment will be expedited and, [ … ]
Fri, 05.11.2021
MagForce AG
Disclosure of an insider information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
MagForce AG: MagForce USA, Inc. has Received FDA's Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Following FDA greenlight, Stage 2b of the [ … ]
Thu, 28.10.2021
MagForce AG
MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights
- Europe: Significant upward trend - both in patient numbers and in the number of centers in Europe offering NanoTherm therapy
- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer successfully completed - Stage 2b with f [ … ]
Mon, 18.10.2021
MagForce AG
FDA announces conditions for the final pivotal study; study
expected to start in 2021 and to be completed in mid-2022; timeframe
largely in line with our expectations; forecasts, price target and BUY
rating confirmed
According to corporate news of 13.10.2021, MagForce AG has made significant
progress in obtaining approval for the treatment of pr [ … ]
Wed, 13.10.2021
MagForce AG
MagForce AG: MagForce USA, Inc. has Received FDA's Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System
Berlin, Germany and Nevada, USA, October 13, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company i [ … ]
Thu, 30.09.2021
MagForce AG
MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain
- Complejo Hospitalario Integral Privado (CHIP) will be first clinic in Spain to offer MagForce's technology for the commercial treatment of brain cancer patients
- Additio [ … ]
Thu, 12.08.2021
MagForce AG
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board
Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual Gener [ … ]